- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01178307
Symptom Inventory for Gastrointestinal Stromal Tumors
Symptom Burden in Patients With Gastrointestinal Stromal Tumors (GISTs)
The goal of this research study is to better understand the symptoms experienced by patients with GIST.
There are 3 parts to this study. In Part 1, participants will complete 1 set of interviews and questionnaires about GIST symptoms. In Part 2, the importance of some symptoms to patients with GIST will be rated by doctors, nurses, patients, and family caregivers. In Part 3, participants will complete questionnaires about GIST symptoms over 1 year.
You are being asked to take part in Part 3 of the study.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Symptom Questionnaires:
If you agree to take part in this study, you will complete questionnaires about symptoms you are having. You will be asked to fill these out 1 time a week during the first 2 months after surgery, 1 time a week during the first 3 months of a new therapy, and every 2 weeks at other times. The questionnaire will ask you to rate how severe your symptoms are and how the symptoms effect the activities of your daily life. The symptom questionnaire should take about 5 minutes to complete. You will complete the questionnaire during the first study visit and at your regular clinic visits.
Between clinic visits, you will be called every 1-2 weeks to complete the questionnaire using an automated telephone system. You can decide what time is most convenient for the automated phone system to call you. If you are not available when the automated system calls, it will call you again at a later time. If you are not reached by the automated phone system after several tries, the study staff will call you. You will be given a secure user name and identification number to use with the automated phone system. The study staff will teach you how to use the automated phone system.
At the clinic visit closest to 3 months after you start the study, you may be seen by a research staff member a second time 1 to 3 days after you completed the symptom questionnaire and asked to fill out the symptom questionnaire again. The research staff member may contact you by phone prior to this clinic visit to arrange times to meet you for the 2 assessments.
Quality-of-Life/Demographic Questionnaires:
At the first visit and the regular clinic visits, you will also rate your overall quality-of-life. This should take about 1 minute to complete.
At the first visit, you will also be asked some demographic questions (such as your age and marital status). Answering these questions should take about 1 minute.
Opinion Questionnaire:
If you are 1 of the first 40 patients enrolled in the study, you will be asked questions about your opinion of the symptom questionnaire at the clinic visit closest to 3 months after you start the study. For example, you will be asked if the symptom questionnaire was easy to understand and complete, and if there were any other questions that should be included. The study staff will use your opinion to decide if changes should be made to the questionnaire or if important symptom questions are missing from the questionnaire. This questionnaire should take about 5 minutes to complete.
Length of Study:
You will be on study for 1 year. You will be off study after you complete the last symptom questionnaire.
This is an investigational study.
Up to 188 participants will take part in this study. Up to 150 participants will be enrolled in Part 3 of this study. All will be enrolled at MD Anderson.
Undersøgelsestype
Tilmelding (Faktiske)
Kontakter og lokationer
Studiesteder
-
-
Texas
-
Houston, Texas, Forenede Stater, 77030
- University of Texas MD Anderson Cancer Center
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Inclusion Criteria:
- 18 years of age or older (Patient and family caregiver only)
- Ability to speak and read English (All participants)
- Residing where IVR service is available (Part 3, Patient only)
- Diagnosis of GIST confirmed by pathological analysis (Patient only)
- Starting new treatment (either surgical or medical) and planning to be followed at M.D. Anderson Cancer Center (Part 3, Patient only)
- Written consent to participate (All participants)
- At least 3 months from start of initial treatment (surgical or medical) for GIST (Part 2, Patient only)
- Family caregiver also willing to receive packet for expert panel participation (Part 2, Patient only)
- Physician or nurse with at least 5 years experience caring for patients with GIST (Professional expert only)
- At least one publication in the last 5 years dealing with GIST (Physician professional expert only)
- Identification as a family caregiver by a patient with GIST (Family caregiver only)
- Patient also willing to receive packet for expert panel participation (Family caregiver only)
Exclusion Criteria:
- Medical condition or impaired performance status that would preclude participation in the study (Patient only)
- Diagnosis of active psychosis or severe cognitive impairment as determined by primary physician (Patient only)
- Active treatment (systemic drug therapy or radiation therapy) for a second malignancy (Patient only)
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Kohorter og interventioner
Gruppe / kohorte |
Intervention / Behandling |
|---|---|
|
Part 1
Patient interview and developmental questionnaires
|
10 minutes to complete 3 questionnaires for development of MDASI-GIST
Andre navne:
Each interview will take approximately 30 minutes.
|
|
Part 2
Content Expert Panel (doctors, nurses) + Patients and Caregivers Questionnaire Development
|
10 minutes to complete 3 questionnaires for development of MDASI-GIST
Andre navne:
|
|
Part 3
Patient MDASI-GIST Questionnaire
|
Every 4 weeks for one year
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Questionnaire Responses to Symptom Inventory for Gastrointestinal Stromal Tumors
Tidsramme: Patients will be followed on study for 1 year regardless of changes in disease stage or treatments.
|
Descriptive statistics used to assess the distributional characteristics and demographics of the study population and to report how patients rate symptom severity and interference with function.
|
Patients will be followed on study for 1 year regardless of changes in disease stage or treatments.
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Loretta A. Williams, PhD, MSN, M.D. Anderson Cancer Center
Publikationer og nyttige links
Hjælpsomme links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Forventet)
Studieafslutning (Forventet)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 2010-0267
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Gastrointestinale stromale tumorer
-
Hospital Universitario Virgen de la ArrixacaIkke rekrutterer endnuLeversygdomme | Levertransplantation | Neoplasmer i leveren | Gastrointestinale stromale tumorer | Metastase | Levermetastaser | Levertransplantation; Komplikationer | Leverkræft | Levertransplantationslidelse | Leverkarcinom | GIST, ondartet | GIST | Metastaser | Metastatisk leverkræft | Gastrointestinal stromal tumor i... og andre forholdSpanien
-
Kura Oncology, Inc.RekrutteringGastrointestinal stromal tumor (GIST) | Gastrointestinal stromal neoplasma | Gastrointestinal stromal tumor, ondartet | Gastrointestinal stromal cancer | Gastrointestinale stromalcelletumorerForenede Stater
-
Centre Leon BerardRekrutteringMetastatisk gastrointestinal stromal tumor | Ikke-operabel gastrointestinal stromal tumor (GIST) | Lokalt avanceret gastrointestinal stromal tumor (GIST)Frankrig
-
National Cancer Institute (NCI)Aktiv, ikke rekrutterendeMetastatisk gastrointestinal stromal tumor | Metastatisk sarkom | Lokalt avanceret sarkom | Lokalt avanceret gastrointestinal stromal tumor | Fase III gastrisk og omental gastrointestinal stromal tumor AJCC v8 | Stadie III tyndtarm, esophageal, kolorektal, mesenterisk og peritoneal gastrointestinal... og andre forholdForenede Stater
-
Kumquat Biosciences Inc.RekrutteringGIST | Gastrointestinale tumorer | GIST - Gastrointestinal Stromal Tumor | Gastrointestinal stromal tumor | GIST Metastatisk kræftForenede Stater
-
Centre Leon BerardRekrutteringC-KIT mutation | Metastatisk gastrointestinal stromal tumor (GIST) | Avanceret gastrointestinal stromal tumor (GIST)Frankrig
-
ARCAGY/ GINECO GROUPRoche Pharma AGAfsluttet
-
National Cancer Institute (NCI)RekrutteringMavekræft | Mave-neoplasma | Gastrointestinal stromal tumor (GIST) | Gastrointestinal stromal sarkom | Gastrointestinal stromal neoplasmaForenede Stater
-
Universität Duisburg-EssenIkke rekrutterer endnuGIST - Gastrointestinal Stromal Tumor | Gastrointestinal stromaltumor (GIST)Tyskland
-
Peking University People's HospitalTilmelding efter invitationGastrointestinal stromal tumor (GIST) | Submucosal tumor i mave-tarmkanalenKina